![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC14A2 |
Gene summary for SLC14A2 |
![]() |
Gene information | Species | Human | Gene symbol | SLC14A2 | Gene ID | 8170 |
Gene name | solute carrier family 14 member 2 | |
Gene Alias | HUT2 | |
Cytomap | 18q12.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q15849 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8170 | SLC14A2 | HCC1 | Human | Liver | HCC | 2.28e-17 | 1.50e+00 | 0.5336 |
8170 | SLC14A2 | HCC2 | Human | Liver | HCC | 6.04e-30 | 1.60e+00 | 0.5341 |
8170 | SLC14A2 | HCC5 | Human | Liver | HCC | 1.94e-30 | 1.81e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC14A2 | SNV | Missense_Mutation | novel | c.1740N>A | p.Phe580Leu | p.F580L | Q15849 | protein_coding | tolerated(0.49) | benign(0.242) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
SLC14A2 | SNV | Missense_Mutation | novel | c.970N>C | p.Ser324Pro | p.S324P | Q15849 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLC14A2 | SNV | Missense_Mutation | rs761664732 | c.1393N>A | p.Glu465Lys | p.E465K | Q15849 | protein_coding | tolerated_low_confidence(0.69) | benign(0.015) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC14A2 | SNV | Missense_Mutation | novel | c.2120N>T | p.Thr707Ile | p.T707I | Q15849 | protein_coding | tolerated(0.29) | benign(0.089) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC14A2 | SNV | Missense_Mutation | novel | c.2507N>T | p.Ala836Val | p.A836V | Q15849 | protein_coding | tolerated(0.08) | benign(0.173) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC14A2 | SNV | Missense_Mutation | novel | c.2681N>T | p.Ala894Val | p.A894V | Q15849 | protein_coding | tolerated(0.11) | possibly_damaging(0.573) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC14A2 | SNV | Missense_Mutation | novel | c.668C>T | p.Ala223Val | p.A223V | Q15849 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SLC14A2 | SNV | Missense_Mutation | novel | c.1732T>G | p.Phe578Val | p.F578V | Q15849 | protein_coding | tolerated(0.2) | benign(0.01) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SLC14A2 | deletion | Frame_Shift_Del | novel | c.1651delN | p.Arg552GlyfsTer13 | p.R552Gfs*13 | Q15849 | protein_coding | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SLC14A2 | SNV | Missense_Mutation | novel | c.2459G>A | p.Gly820Glu | p.G820E | Q15849 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DD-A4NK-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8170 | SLC14A2 | TRANSPORTER | nifedipine | NIFEDIPINE | 17344938 |
Page: 1 |